Novartis AG

NVS · SWISS

$151.12−$5.15 (−3.30%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $156.27

NVS analyst rating

HoldConsensus of 5 analysts over the last 12 months. 40% rate it a buy.

Strong buy0
Buy2
Hold3
Underperform0
Sell0

12-month price target · 26 analysts

Average $155.66 (+3.0% upside)

Low: $121.31
Now: $151.12
High: $191.08

Upgrades and downgrades

The latest rating actions, newest first

NVS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HSBC	Sep 10, 2026	Upgrade	Reduce → Hold	$123.00 → $136.00	59%
Morgan Stanley	Mar 26, 2026	Maintains	Overweight	$143.00 → $170.00	50%
Barclays	Jan 6, 2026	Upgrade	Underweight → Equal-Weight	—	0%
JP Morgan	Dec 8, 2025	Upgrade	Neutral → Overweight	—	56%
Jefferies	Oct 27, 2025	Initiates	Hold	—	80%

The case for and against

Updated Nov 29, 2024

Bull case

Novartis demonstrates a robust outlook supported by the strong performance of its key drug Cosentyx, which achieved 25% year-over-year growth due to successful label expansions and market uptake. The firm has raised its 2024 financial outlook, indicating positive sales trends across multiple therapeutic areas, with potential for further growth stemming from unmodeled pipeline assets that may prove clinically effective. Additionally, the long lifecycle and targeted approach of Scemblix, alongside the promising revenue potential from other therapies, position Novartis favorably for continued financial success.

Bear case

The negative outlook on Novartis's stock is influenced by concerns regarding the clinical viability of its late-stage assets, which, if proven unviable, could exert downward pressure on share prices. Furthermore, any shortfalls in sales relative to projections or consensus estimates may lead to additional negative impacts on stock value. Additionally, potential delays or rejections in the approval process for new pipeline assets and label-expanding initiatives could adversely affect future cash flow and overall valuation, compounded by external factors such as unfavorable policy developments or economic downturns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.